Phase 2 (Interim immunogenicity and safety data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: NVX-CoV2373 in COVID-19 - Phase 2 (Interim immunogenicity and safety data)
ClinicalTrial.gov (NCT04368988): Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
COVID-19 Vaccine Candidate
05-11-2020 Reports First Quarter 2020 Financial Results
Ebola Vaccine Candidate
05-2020: NVX-CoV2373 Vaccine for COVID-19
06-2020: Corporate Updated (slide 5-12)
08-2020: NVX-CoV2373 COVID-19 Vaccine Candidate Phase 1/2, Part 1, Clinical Trial Results
2020: Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. The New England Journal of Medicine
MECHANISM OF ACTION/RATIONALE
NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology
Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies
NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization.
Updated by HC
#NVAX, #NVX-CoV2373, #COVID-19, #Vaccine
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post